Updates are available Correction dated 2025-02-13
Click to view Correction: https://doi.org/10.1007/s10120-025-01591-0
-
Authors
Takizawa, Kohei https://orcid.org/0000-0002-7702-0427
Ono, Hiroyuki
Hasuike, Noriaki
Takashima, Atsuo
Minashi, Keiko
Boku, Narikazu
Kushima, Ryoji
Katayama, Hiroshi
Ogawa, Gakuto
Fukuda, Haruhiko
Fujisaki, Junko
Oda, Ichiro
Yano, Tomonori
Hori, Shinichiro
Doyama, Hisashi
Hirasawa, Kingo
Yamamoto, Yoshinobu
Ishihara, Ryu
Tanabe, Satoshi
Niwa, Yasumasa
Nakagawa, Masahiro
Terashima, Masanori
Muto, Manabu
,
-
Funding
Funding for this research was provided by:
National Cancer Center Research and Development Fund (23-A-16, 23-A-19, 26-A-4, 29-A-3, 2020-J-3)
Health and Labor Sciences Research Grants for Clinical Cancer Research (22-021, 25-008)
- License Information
-
More Information
Article History
Received: 20 August 2020
Accepted: 16 October 2020
First Online: 8 November 2020
Change Date: 13 February 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10120-025-01591-0
Compliance with ethical standards
:
: Kohei Takizawa has received personal fees from Takeda Pharmaceutical, Otsuka Pharmaceutical, EA Pharma, Boston Scientific, AstraZeneca, Taiho Pharmaceutical. Hiroyuki Ono has received personal fees from Otsuka Pharmaceutical, Daiichi-Sankyo, EA Pharma, Boston Scientific, AstraZeneca, Olympus. Keiko Minashi has received research funding from Ono Pharmaceutical, MSD K.K., Mediscience Planning Inc, Merck Biopharma Co., Ltd, and Astellas Pharma Inc. Narikazu Boku has received research funding from Ono Pharmaceutical, Takeda Pharmaceutical and personal fees from Ono Pharmaceutical, Taiho Pharmaceutical, and Bristol-Myers Squibb. Ryoji Kushima has received personal fees from Takeda Pharmaceutical, EA Pharma, AstraZeneca, Otsuka Pharmaceutical, Novartis, and Chugai Pharmaceutical. Hiroshi Katayama has received personal fees from Johnson & Johnson. Haruhiko Fukuda has received personal fees from Chugai Pharmaceutical. Tomonori Yano has received research funding from Olympus, FUJIFILM and personal fees from Olympus. Shinichiro Hori has received personal fees from FUJIFILM Corporation, FUJIFILM Medical Co., Ltd., and Kaneka Medix Corporation. Hisashi Doyama has received personal fees from Otsuka Pharmaceutical, EA Pharma, AstraZeneca, Daiichi Sankyo, Olympus medical systems. Ryu Ishihara has received personal fees from EA Pharma, AstraZeneca, Ono Pharmaceutical, MSD, Olympus, and FUJIFILM. Satoshi Tanabe has received personal fees from AstraZeneca, Takeda Pharmaceutical, EA Pharma. Masanori Terashima has received personal fees from Taiho Pharmaceutical, Chugai Pharmaceutical, Ono Pharmaceutical, Bristol-Myers Squibb, Yakult Honsha, Takeda Pharmaceutical, Eli Lilly, Pfizer, and Daiichi Sankyo. Manabu Muto has received research funding from Olympus and Ono Pharmaceutical for clinical trial. All remaining authors have declared no conflicts of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the Helsinki Declaration of 1964 and later versions. This study was approved by the institutional review boards of all participating hospitals. Informed consent was obtained from all patients.
Free to read: This content has been made available to all.
